Page last updated: 2024-11-02

pantoprazole and Neoplasm Metastasis

pantoprazole has been researched along with Neoplasm Metastasis in 1 studies

Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.

Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hansen, AR1
Tannock, IF1
Templeton, A1
Chen, E1
Evans, A1
Knox, J1
Prawira, A1
Sridhar, SS1
Tan, S1
Vera-Badillo, F1
Wang, L1
Wouters, BG1
Joshua, AM1

Trials

1 trial available for pantoprazole and Neoplasm Metastasis

ArticleYear
Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
    The oncologist, 2019, Volume: 24, Issue:9

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Disease Progress

2019